Resources For:
Medical & Allied Professionals, Healthcare & Researchers
THE CHOLANGIOCARCINOMA NEXUS:
The Convergence of Great Minds in Science, Innovation, Medical Expertise, Lived Experience, and Community—A Constant Catalyst in the Evolution of Success.
‘Chol’ means bile ➡ ‘angio’ means vessel or ducts ➡ ‘carcinoma’ means a cancer that originates in the protective layer that lines the ducts (the epithelial layer).
Events & Symposiums
Standardisation of Cholangiocarcinoma Treatment Pathways
The recording has been sent to all registered attendees. For clinicians and medical professionals who missed this event, please contact admin@cholangio.org
If you missed this webinar: Request a recording
A Zoom webinar hosted by the Cholangiocarcinoma Foundation Australia:
“An Update on MoST / CaSP-Specific Cholangiocarcinoma Data and Standardisation of Australian Treatment Pathways”
Presented by:
- Professor David Thomas (Founder and Chief Strategy Officer, Omico)
- Professor John Zalcberg (Head of Cancer Research Program, Monash University)
- Professor Juan Valle (Chief Medical Officer, Cholangiocarcinoma Foundation USA)
Objective
This webinar will explore management options for cholangiocarcinoma, a rare and aggressive cancer, with a focus on patients presenting at stage four. Discussions will include:
- The benefits of comprehensive genomic profiling
- Potential clinical trial matching
- Updates on the standardisation of treatment pathways in Australia
- Beyond Cis-Gem Durvalumab in advanced biliary tract cancers
Event Details
- Date: Tuesday, 28th January
- Time: 5:30 PM – 6:30 PM (AEDT)
- Location: Online (Zoom)
- Click Here to Register
Agenda
5:30 – 5:35 PM
Introduction to speakers by Dr. Natalie Rickers (Director, Research and Strategy, Cholangiocarcinoma Foundation Australia)
5:35 – 5:50 PM
Genetic Testing and MoST/CaSP Cholangiocarcinoma-Specific Data
Presented by Professor David Thomas
5:50 – 6:05 PM
Standardisation of Australian Treatment Pathways
Presented by Professor John Zalcberg
6:05 – 6:20 PM
Beyond Cis-Gem Durvalumab in Advanced BTC
Presented by Professor Juan Valle
6:20 – 6:30 PM
Q&A Session
About the Speakers
Professor David Thomas
Founder and Chief Strategy Officer, Omico
Professor Thomas is a leading authority in genomic oncology, integrating genomic profiling into clinical care to enable personalized treatment strategies. His pioneering work has transformed the management of rare and aggressive cancers, including cholangiocarcinoma.
Professor John Zalcberg, AO, MBBS, PhD, FRACP, FRACMA, FAHMS
Head of Cancer Research Program, School of Public Health and Preventive Medicine, Monash University
Professor Zalcberg is an internationally recognized oncologist and researcher. As a co-founder of the Australasian Gastrointestinal Trials Group (AGITG), his contributions to gastrointestinal cancer research and policy have shaped cancer care in Australia. He is a recipient of the Officer of the Order of Australia (AO) for his services to oncology.
Professor Juan Valle, MB ChB, MSc, FRCP
Chief Medical Officer, Cholangiocarcinoma Foundation USA (Special Guest)
Professor Valle is a globally respected expert in hepatobiliary cancers. As the first Chief Medical Officer of the Cholangiocarcinoma Foundation USA, he leads initiatives to advance research and care for this challenging cancer type. His groundbreaking work has significantly impacted the understanding and treatment of biliary tract cancers globally.
About the Organisations
This webinar is an opportunity to connect with global experts, gain insights into cutting-edge approaches, and contribute to shaping the future of cholangiocarcinoma care in Australia.
About Omico
https://www.omico.com.au/
Omico is a national, not-for-profit organisation pioneering the integration of genomic profiling into cancer care. By leveraging precision oncology, Omico connects patients with personalised treatment options and innovative clinical trials, accelerating breakthroughs in cancer management across Australia.
About Cholangiocarcinoma Foundation Australia
www.cholangio.org
The Cholangiocarcinoma Foundation Australia is dedicated to transforming the landscape for bile duct cancer and bile-related diseases. Through research, advocacy, and education, we address the critical challenges posed by cholangiocarcinoma, focusing on prevention, early detection, and empowering patients to understand and respond effectively.
We look forward to welcoming you!
Kind regards,
Steve
Subscribe to be advised of upcoming webinars, interviews, and updates.
2025: TBC
Manuscript Release: Controversies of Biliary Tract Cancer Management. Prof’s Goldstein, Pilgram, Zalcberg.
2025: TBC
The Cancer Care Pathway for Cholangiocarcinoma. A Guide for Clinicians. Project lead – Melanie Regan
2025: TBC
Int’l CCA Research Network and ENS-CCA (European group)
International Consensus on Research Priorities
Establish the top 10 Research Priorities: 12th Annual Cholangiocarcinoma Foundation’s Annual Conference as part of the International Consensus on Research Priorities. This is a joint initiative between CCF’s International Cholangiocarcinoma Research Network (ICRN) and the European Cooperation in Science and Technology (COST)-Action: Precision-BTC-Network, part of the European Network for the Study of Cholangiocarcinoma (ENS-CCA).
Resource Library
Cure Cholangiocarcinoma Think Tank (C2T2)
The Cholangiocarcinoma Foundation has published a white paper from the first Cure Cholangiocarcinoma Think Tank (C2T2 ) meeting, which gathered 29 expert scientists and clinicians from the world’s leading academic institutions. The multi-disciplinary group was led by Dr. Mitesh Borad and Dr. Nilo Azad, chairs of the International Cholangiocarcinoma Research Network (ICRN). Topics selected for the first C2T2 meeting reflected areas of urgency and opportunity for improving outcomes for people impacted by CCA – precision early diagnostics and prevention and precision therapeutics (specifically in the immune-oncology space).
“Because a thing seems difficult, do not think it impossible.” – Marcus Aurelius
